{"id":40090,"date":"2021-09-30T10:34:03","date_gmt":"2021-09-30T10:34:03","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=40090"},"modified":"2021-10-12T05:26:39","modified_gmt":"2021-10-12T05:26:39","slug":"neuroprotective-potentials-of-cocculus-hirsutus-leaf-extract-against-67-epoxytropine-tropate-induced-memory-impairment-in-rats","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol14no3\/neuroprotective-potentials-of-cocculus-hirsutus-leaf-extract-against-67-epoxytropine-tropate-induced-memory-impairment-in-rats\/","title":{"rendered":"Neuroprotective Potentials of Cocculus hirsutus Leaf Extract Against 6,7-Epoxytropine Tropate-Induced Memory Impairment in Rats"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

6,7-Epoxytropine tropate (Scopolamine), also known as Hyoscine, is a natural belladonna alkaloid that competes with acetylcholine and non-selectively inhibits muscarinic receptors1<\/sup>. Its high affinity towards muscarinic receptors makes more suitable as\u00a0preanesthetic medication to treat post-operative emesis and also effective to prevent motion sickness2<\/sup>. It readily permeates blood brain barrier and inhibits central muscarinic receptors that reduces post ganglionic cholinergic nerve stimulation results in transient cognitive\u00a0impairment and neurophysiological changes3<\/sup>.Administration of scopolamine can be used as psychopharmacological experimental model of Alzheimer\u2019s disease (AD)4<\/sup>.<\/p>\n

Transient and progressive cognitive impairment is due to deficiency of acetylcholine levels in the basal forebrain is one of the chief causes of AD5<\/sup>. Alzheimer\u2019s disease etiopathogenesis may also include extracellular deposits of senile plaques of beta-amyloid,\u00a0intracellular aggregation of neurofibrillary tau protein tangles and increased oxidative stress6<\/sup>. Cholinergic neurodegeneration in Alzheimer\u2019s disease results in deficiency of acetylcholine at the areas of brain that causes impairment in cognitive functions like learning, thinking and\u00a0memory7<\/sup>.Acetylcholinesterase enzyme inhibition is a significant target strategy for senile dementia by enhancing the levels of acetylcholine8<\/sup>. One of the major determinants for Alzheimer\u2019s is oxidative stress that stimulates death of neuronal cells and plays a crucial role\u00a0in neurobiochemical changes such as decreased levels of reduced glutathione and catalase activity9<\/sup>.Existing drugs have been approved to relieve some cognitive symptoms in Alzheimer\u2019s disease10<\/sup>. On the other side, pharmacological effects of natural products seem to\u00a0be advantageous in the treatment of neuropsychological and neurotoxicological disorders with no or fewer side-effects11<\/sup>.<\/p>\n

Cocculus hirsutus\u00a0<\/em>(Menispermaceae) commonly referred to as \u201cPatalgarudi (Sanskrit)\u201d grows in India and many other countries in Asia. The leaves are ovate, obtuse, sub deltoid with soft hairs on both sides12<\/sup>. The traditional and research evidences support the use of\u00a0various parts of Cocculus hirsutus<\/em>as detoxifier, diuretic, antidiabetic, antipyretic, analgesic and anti-inflammatory agents13-15<\/sup>.Currently the neuroprotective potentials were less explored from the leaf of Cocculus hirsutus.\u00a0<\/em>Thus, the goal of our current pharmacological research was to demonstrate the neuroprotective potentials of Cocculus hirsutus<\/em>leaf extract in rats against memory impairment induced by scopolamine.<\/p>\n

Materials and Methods<\/strong><\/p>\n

Experimental animals<\/strong><\/p>\n

For the study, healthy wistar albino rats of both sexes weighing 180\u00b120 g were used. The animals were housed in standard propylene cages and were kept in regulated environmental conditions at 25\u00b12\u00b0C temperature, 30-60% Humidity and 12 hrcycles of light \/\u00a0dark. With typical pellet diet and water ad libitum<\/em>, they were acclimatized to hygienic laboratory conditions for 2 weeks. The Institutional Animal Ethical Committee (IAEC) of\u00a0Vignan Institute of Pharmaceutical Technology under registration number No. 2003\/PO\/Re\/S\/18\/CPCSEA, dated 09\/02\/2018 approved the research protocol and all the\u00a0studies were performedwith the IAEC and CPCSEA guidelines and regulations.<\/p>\n

Collection of fruits and Preparation of the pulp extract<\/strong><\/p>\n

The fresh leaves of Cocculus hirsutus<\/em>were procured from Visakhapatnam, A.P., India and authenticated in Department of Botany, Andhra University, Visakhapatnam, A.P., India. The fresh leaves were collected, dried under shade conditions and powdered mechanically.\u00a0 Cocculus hirsutus\u00a0<\/em>leaf hydroalcoholic extract was prepared by using Soxhlet extraction for 48 hr. The extracted liquid was concentrated by placing on water bath, air dried overnight at\u00a0room temperature and the final extract was stored in a refrigerator at 3\u00b11\u00b0C.<\/p>\n

Acute toxicity study of Cocculus hirsutus <\/em>leaf extract<\/strong><\/p>\n

The extract was evaluated for acute toxicity in rats according to OECD guideline No. 42516<\/sup>. The rats were fasted overnight prior to dosing and the dosage was calculated based on the fasted body weight. Single doses of 2000 mg\/kg of Cocculus hirsutus\u00a0<\/em>leaf hydroalcoholic\u00a0extract was administered to the rats orally by gavage using a suitable intubation cannula. After administration, food was withheld for an additional 3-4 hr and monitored continuously for any toxic signs. The rats were kept under observation with a duration of 14 days for any\u00a0mortality, weight, physiological and psychological changes. This study reported that hydroalcoholic leaf extract ofCocculus hirsutus<\/em>has LD50<\/sub>>2000 mg\/kg body weight.<\/p>\n

Experimental protocol and dosage regimen<\/strong><\/p>\n

The experimental animals were segregated in to five groups of six rats each. According to acute toxicity data, 200 mg\/kg and 400 mg\/kg of test compound have been chosen for administration. In Group I, the rats were treated with normal saline (0.9%w\/v, 1\u00a0ml\/kg body weight, orally) to serve as normal control. In Group II, treatment of rats with scopolamine (1 mg\/kg body weight, i.p.) dissolved in normal saline to serve as negative control. In Group III, rats were simultaneously treated with donepezil (2 mg\/kg body weight,\u00a0orally) and scopolamine (1 mg\/kg body weight, i.p.) dissolved in normal saline to serve as a positive control. In Group IV, rats were simultaneously treated with Cocculus hirsutus\u00a0<\/em>leaf extract (200 mg\/kg body weight, orally) and scopolamine (1 mg\/kg body weight,\u00a0i.p.) dissolved in normal saline. In Group V, rats were simultaneously treated with Cocculus hirsutus<\/em>leafextract (400 mg\/kg body weight, orally) and scopolamine (1 mg\/kg body weight, i.p.) dissolved in normal saline. All the drugs were given for 14 consecutive days to all the\u00a0representative groups with standard pellet diet and water ad libitum<\/em>. The assessment of cognitive functions was carried out 30 min after scopolamine administration to the respective groups. For assessment of biochemical changes in the brain, the animals were sacrificed,\u00a0brain was excised, washed with frozen saline, homogenized and frozen at -20\u00b0C for further use.<\/p>\n

Behavioral parameters <\/strong><\/p>\n

Morris water maze test<\/strong><\/p>\n

Morris water navigation task was widely accepted for testing visual short-term memory and visual-spatial learning in rodents by observing and recording the escape latency time to reach the submerged invisible platform17<\/sup>. In this test, the maze consisted of black\u00a0colored circular water pool (diameter 120 cm, height 50 cm) filled with water to 40 cm in depth. The maze was held at 25\u00b12\u00b0C and was surrounded with various visual cues of different shapes. The pool was undisturbed and maintained the position of cues constant on\u00a0all the days of experimentations. The maze was essentially divided into four equally spaced quadrants designed as North, South, East and West. In one of the quadrants, a black colored circular invisible platform with a diameter of 10 cm was fixed constantly 1 cm below the\u00a0water surface so that the rat could escape from swimming. The rats were acclimatized to reach hidden platform in 120 s for a week with a minimum of five training sessions per day. The time taken to reach invisible platformby the treated rats was recorded as Escape Latency Time (ELT).<\/p>\n

Elevated plus maze test<\/strong><\/p>\n

Elevated plus maze was widely used paradigm for evaluating the exteroceptive learning and memory in rodents by observing and recording the transfer latency time to reach any closed arm from the end of open arm\u00a018-20<\/sup>.For rats, the maze consisted of a central dais\u00a0(10 x 10 cm) with four arms radiating outwards i.e. two open arms (50 x 10 cm) alternative with two closed arms (50 x 10 x 20 cm), arranged at an angle of 90\u02da degrees from each other. The height of plus maze was 50 cm from the ground level. On the 14th<\/sup> day of treatment period, after administration of drugs to the respective groups, each rat was positioned at the\u00a0end of the open arm facing the central platform and the transfer latency time was recorded which reflects the acquisition of learning behavior of rats. The rats were acclimatized for 120 s to the maze and relocated to its home cage. After 24 hr of acquisition trail, the transfer\u00a0latency time of each rat was documented that reflects the retention of information or memory. The time taken by the rats to reach any of the closed arms with all their four legs from the end of open arm is known as Transfer Latency Time (TLT). The maze was cleaned properly with\u00a0wet tissue paper after each experiment to avoid the influence of residual stimuli if any.<\/p>\n

Neurobiochemical parameters <\/strong><\/p>\n

After behavioral studies, rats were anesthetized under light ether and deliberately euthanized to evade any damage to the brain tissueby cervical dislocation. The entire brain tissue was immediately removed from the sacrificed rats, washed with ice-cold normal saline and the brains regions were separated. The tissue homogenate of different brain regions was\u00a0used for analysis of neurobiochemical parameters such as acetylcholinesterase activity21<\/sup>, reduced glutathione levels22<\/sup> and catalase activity23<\/sup>.<\/p>\n

Brain acetylcholinesterase activity<\/strong><\/p>\n

Brain acetylcholinesterase activity was performed based on Ellaman\u2019s photometric method in 1961 with minor modifications24<\/sup>. By using Teflon homogenizer, the hippocampal regions of the brains were homogenized with Tris HCl buffer (100 mM, pH 8) to prepare 10% homogenate. To 25 \u00b5L of supernatant, 50 \u00b5L of acetylthiocholine iodide (20 mM) and\u00a0925 \u00b5L of Ellman reagent (0.5 mM) prepared in Tris HCl buffer (100 mM, pH 8) were added. The degradation of acetylthiocholine iodide has been read at 412 nm and the outcomes were reported as \u00b5mols of acetylthiocholine hydrolyzed per milligram of protein (brain tissue) per minute.<\/p>\n

Brain reduced glutathione levels<\/strong><\/p>\n

Brain levels of reduced glutathione were assessed according to the standard protocol described by Leopold Flohe and Wolfgand A. Gunzler (1984)25<\/sup>.Briefly, the brain hemispheres were homogenized with phosphate buffer (0.1 M, pH 7.4) to prepare 5%\u00a0homogenate and centrifuged for 10 min at 4\u00b0C at 1500 rpm. After centrifugation, the supernatant collected was used to analyze the levels of glutathione peroxidase. The activity of Glutathione peroxidase was stated as \u00b5mol of GSH utilized per milligram of protein per minute at 37\u00b0C.<\/p>\n

Brain catalase activity<\/strong><\/p>\n

The activity of brain catalase was assayed according to colorimetric technique of Sinha (1972)26<\/sup>. 1 mL of brain tissue homogenate in 5 mL phosphate buffer (pH 7.4) was combinedin 4 mL of H2<\/sub>O2<\/sub> (0.2 M) in phosphate buffer. After 3 min of adding H2<\/sub>O2, <\/sub>dichromate acetic acid (2 mL) was added to 1 mL of above-mentionedreaction mixture. The final reaction mixture was placed in hot water bath for 10 min, cooled under running tap water and record the absorbance against blank at 540 nm. The activity of brain catalase was expressed as \u00b5mol of H2<\/sub>O2 <\/sub>consumed per milligram of protein per minute at 37\u210327<\/sup>.<\/p>\n

Statistical Analysis<\/strong><\/p>\n

All findings are expressed as Mean \u00b1 Standard Error of the Mean (n<\/em>=6) and assessed by Analysis of Variance (ANOVA) accompanied by Bonferroni post tests for multiple comparative studies using Graph Pad Prism application, version 5.0. The \u201cP<\/em>\u201d value p<\/em><0.001was considered as statistically significant.<\/p>\n

Results<\/strong><\/p>\n

Effect of Cocculus hirsutus\u00a0<\/em>leaf extract on escape latency in scopolamine treated rats using Morris water navigation task<\/strong><\/p>\n

Escape Latency Time was considered as parameter to test the impact of Cocculus hirsutus<\/em>leafextract on spatial learning and memory in rats with dementia caused by scopolamine. The rats treated with scopolamine showed a significant increase in ELT than\u00a0the saline treated controls (*<\/sup>p<\/em><0.001) indicating the impairment of cognition (Figure 1). Administration of Cocculus hirsutus<\/em>leafextract (200 mg\/kg and 400 mg\/kg) was found that the ELT was significantly reduced ($<\/sup>p<\/em><0.001) and decreased the effects of scopolamine as\u00a0compared with ($<\/sup>p<\/em><0.001) group alone treated with scopolamine (Table 1).<\/p>\n\n\n\n
\"Vol14No3_Neu_Uma_fig1\"<\/a><\/td>\nFigure 1: Effect on escape latency time in scopolamine treated rats.<\/strong><\/p>\n

Click here to view figure\u00a0<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 1: Effect of Cocculus hirsutus <\/em>leaf extract and standard drug donepezil on escape latency in scopolamine treated rats.<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Groups<\/strong><\/td>\nTreatment<\/strong><\/td>\nDay 7<\/strong><\/td>\nDay 10<\/strong><\/td>\nDay 14<\/strong><\/td>\n<\/tr>\n
Group I<\/td>\nNormal saline<\/p>\n

(0.9 %W\/V, 1 ml\/kg)<\/td>\n

31.63\u00b10.38<\/td>\n26.81\u00b10.50<\/td>\n21.76\u00b10.31<\/td>\n<\/tr>\n
Group II<\/td>\nScopolamine<\/p>\n

(1 mg\/kg)<\/td>\n

65.40\u00b10.18*<\/sup><\/td>\n72.98\u00b10.28*<\/sup><\/td>\n81.35\u00b10.51*<\/sup><\/td>\n<\/tr>\n
Group III<\/td>\nDonepezil+ Scopolamine<\/p>\n

(2 mg\/kg + 1 mg\/kg)<\/td>\n

30.57\u00b10.38$<\/sup><\/td>\n25.82\u00b10.48$<\/sup><\/td>\n21.87\u00b10.31$<\/sup><\/td>\n<\/tr>\n
Group IV<\/td>\nExtract + Scopolamine<\/p>\n

(200 mg\/kg + 1 mg\/kg)<\/td>\n

65.21\u00b10.23$#<\/sup><\/td>\n58.23\u00b10.28$#<\/sup><\/td>\n53.9\u00b10.31$#<\/sup><\/td>\n<\/tr>\n
Group V<\/td>\nExtract + Scopolamine<\/p>\n

(400 mg\/kg + 1 mg\/kg)<\/td>\n

56.37\u00b10.21$#<\/sup><\/td>\n52.76\u00b10.13$#<\/sup><\/td>\n46.33\u00b10.27$#<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Results are expressed as Mean\u00b1SEM (n=6). SEM = Standard error mean. The statistically significant difference has been determined by ANNOVA accompanied by Bonferroni post tests for multiple comparison and are statistically significant with \u2018*\u2019p<\/em><0.001 compared with\u00a0the control group, \u2018$<\/sup>\u2019p<\/em><0.001 compared with the negative control, \u2018#<\/sup>\u2019p<\/em><0.001 compared with the positive control. ANNOVA = Analysis of variance.<\/p>\n

Effect of Cocculus hirsutus\u00a0<\/em>leaf extract on transfer latency in scopolamine treated rats using elevated plus maze test.<\/strong><\/p>\n

Transfer Latency Time was used to test the impact of Cocculus hirsutus<\/em>leafextracton acquisition of learning and retention of memory in rats with dementia caused by scopolamine. The rats treated with scopolamine showed remarkable increase in TLT than the saline treated\u00a0controls (p<\/em><0.001) indicating the impairment of memory and learning (Figure 2). The animals treated with Cocculus hirsutus<\/em>leafextract(200 mg\/kg and 400 mg\/kg) showed significant decrease (p<\/em><0.001) in TLT indicating substantial improvement in learning and\u00a0memory and decreases the effects of scopolamine as compared with that of reference standard donepezil (1mg\/kg) (Table 2).<\/p>\n\n\n\n
\"Vol14No3_Neu_Uma_fig2\"<\/a><\/td>\nFigure 2: Effect on transfer latency time in scopolamine treated rats.<\/strong><\/p>\n

Click here to view figure\u00a0<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 2: Effect of Cocculus hirsutus <\/em>leaf extract and standard drug donepezil on transfer latency in scopolamine treated rats.<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Groups<\/strong><\/td>\nTreatment<\/strong><\/td>\nAcquisition trial<\/strong><\/td>\nRetention trial<\/strong><\/td>\n<\/tr>\n
Group I<\/td>\nNormal saline<\/p>\n

(0.9 %W\/V, 1 ml\/kg)<\/td>\n

24.53\u00b10.40<\/td>\n22.87\u00b10.23<\/td>\n<\/tr>\n
Group II<\/td>\nScopolamine<\/p>\n

(1 mg\/kg)<\/td>\n

28.70\u00b10.36*<\/sup><\/td>\n26.57\u00b10.28*<\/sup><\/td>\n<\/tr>\n
Group III<\/td>\nDonepezil+ Scopolamine<\/p>\n

(2 mg\/kg + 1 mg\/kg)<\/td>\n

14.69\u00b10.27$<\/sup><\/td>\n12.36\u00b10.17$<\/sup><\/td>\n<\/tr>\n
Group IV<\/td>\nExtract + Scopolamine<\/p>\n

(200 mg\/kg + 1 mg\/kg)<\/td>\n

22.08\u00b10.20$#<\/sup><\/td>\n18.94\u00b10.26$#<\/sup><\/td>\n<\/tr>\n
Group V<\/td>\nExtract + Scopolamine<\/p>\n

(400 mg\/kg + 1 mg\/kg)<\/td>\n

17.95\u00b10.12$#<\/sup><\/td>\n15.96\u00b10.23$#<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Results are expressed as Mean\u00b1SEM (n=6). SEM = Standard error mean. The statistically significant difference has been determined by ANNOVA accompanied by Bonferroni post tests for multiple comparison and are statistically significant with \u2018*\u2019p<\/em><0.001 compared with\u00a0the control group, \u2018$<\/sup>\u2019p<\/em><0.001 compared with the negative control, \u2018#<\/sup>\u2019p<\/em><0.001 compared with the positive control. ANNOVA = Analysis of variance.<\/p>\n

Neurobiochemical Assessment<\/strong><\/p>\n

Effect on brain acetylcholinesterase activity <\/strong><\/p>\n

Administration of scopolamine markedly increase the degradation of acetylcholine as indicated by significant enhancement in the activity of acetylcholinesterase (*<\/sup>p<\/em><0.001) in the hippocampal region of rat\u2019s brain as compared to the control group (Figure 3A). Concurrent\u00a0administration of donepezil and scopolamine showed significant reduction in acetylcholinesterase activity ($<\/sup>p<\/em><0.001) in hippocampus compared with the negative control. Furthermore, Cocculus hirsutus\u00a0<\/em>leaf extract(200 mg\/kg and 400 mg\/kg) treated groups\u00a0exhibited significant decrease in acetylcholinesterase activity in the hippocampal region of rat\u2019s brain when compared with ($<\/sup>p<\/em><0.001) group alone treated with scopolamineand (#<\/sup>p<\/em><0.001) positive control (Table 3).<\/p>\n

Effect on brain reduced glutathione levels <\/strong><\/p>\n

Chronic scopolamine administration to rats resulted in oxidative stress as shown by significant decline in the levels of reduced glutathione (*<\/sup>p<\/em><0.001) when compared to saline treated rats (Figure 3B). Donepezil significantly inhibited the effects of scopolamine and\u00a0marked increase in reduced glutathione levels ($<\/sup>p<\/em><0.001) when compared to scopolamine-alone treated group (negative control). The co-administration of Cocculus hirsutus\u00a0<\/em>leaf extract(200 mg\/kg and 400 mg\/kg) and scopolamine significantly reverses the\u00a0decline the levels of reduced glutathione induced by scopolamine ($<\/sup>p<\/em><0.001). The Cocculus hirsutus\u00a0<\/em>leaf extract treated groups showed significant difference when measured with (#<\/sup>p<\/em><0.001) positive control (Table 3).<\/p>\n

Effect on brain catalase activity <\/strong><\/p>\n

Administration of scopolamine to the rats prominently increases the oxidative damage by significant decrease in the activity of catalase (*<\/sup>p<\/em><0.001) when compared to the normal control (Figure 3C). Concurrent administration of donepezil and scopolamine to the rats showed significant rise in the catalase activity by inhibiting the effects of scopolamine when\u00a0compared to those administered with scopolamine-alone ($<\/sup>p<\/em><0.001). Combined administration of Cocculus hirsutus<\/em>leafextract (200 mg\/kg and 400 mg\/kg) and scopolamine in rats resulted in significant increase of catalase activity when compared with negative control ($<\/sup>p<\/em><0.001). The extract treated groups also exhibited significant difference when measured with (#<\/sup>p<\/em><0.001) positive control (Table 3).<\/p>\n

Table 3: Effect of Cocculus hirsutus <\/em>leaf extract and standard drug donepezil on neurobiochemical levels in scopolamine treated rats.<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Groups<\/strong><\/td>\nTreatment<\/strong><\/td>\nAChE activity (\u00b5mol\/mg protein\/min) <\/strong><\/td>\nReduced Glutathione levels (\u00b5mol\/mg protein\/min)<\/strong><\/td>\nCatalase activity (\u00b5mol\/mg protein\/min)<\/strong><\/td>\n<\/tr>\n
Group I<\/td>\nNormal saline<\/p>\n

(0.9 %W\/V, 1 ml\/kg)<\/td>\n

10.70\u00b10.19<\/td>\n26.27\u00b10.15<\/td>\n96.10\u00b10.09<\/td>\n<\/tr>\n
Group II<\/td>\nScopolamine<\/p>\n

(1 mg\/kg)<\/td>\n

24.60\u00b10.24*<\/sup><\/td>\n11.61\u00b10.15*<\/sup><\/td>\n30.80\u00b10.16*<\/sup><\/td>\n<\/tr>\n
Group III<\/td>\nDonepezil+ Scopolamine<\/p>\n

(2 mg\/kg + 1 mg\/kg)<\/td>\n

11.83\u00b10.26$<\/sup><\/td>\n25.09\u00b10.17$<\/sup><\/td>\n89.09\u00b10.11$<\/sup><\/td>\n<\/tr>\n
Group IV<\/td>\nExtract + Scopolamine<\/p>\n

(200 mg\/kg + 1 mg\/kg)<\/td>\n

19.75\u00b10.34$#<\/sup><\/td>\n18.55\u00b10.17$#<\/sup><\/td>\n65.21\u00b10.25$#<\/sup><\/td>\n<\/tr>\n
Group V<\/td>\nExtract + Scopolamine<\/p>\n

(400 mg\/kg + 1 mg\/kg)<\/td>\n

16.41\u00b10.17$#<\/sup><\/td>\n23.47\u00b10.16$#<\/sup><\/td>\n85.61\u00b10.19$#<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Results are expressed as Mean\u00b1SEM (n=6). SEM = Standard error mean. The statistically significant difference has been determined by ANNOVA accompanied by Bonferroni post tests for multiple comparison and are statistically significant with \u2018*\u2019p<\/em><0.001 compared with\u00a0the control group, \u2018$<\/sup>\u2019p<\/em><0.001 compared with the negative control, \u2018#<\/sup>\u2019p<\/em><0.001 compared with the positive control. ANNOVA = Analysis of variance.<\/p>\n\n\n\n
\"Vol14No3_Neu_Uma_fig3\"<\/a><\/td>\nFigure 3: Effects on neurobiochemical parameters in scopolamine treated rats (a) Acetylcholinesterase activity (b) Reduced Glutathione levels (c) Catalase activity.<\/strong><\/p>\n

Click here to view figure\u00a0<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Discussion<\/strong><\/p>\n

Alzheimer\u2019s is a transient, heterogenous and progressive neurodegenerative disease characterized by agnosia, aphasia and apraxia with the loss of memory and cognitive dysfunction28<\/sup>. Collective evidences suggested AD\u2019s behavioral and cognitive symptoms of contributed to impaired neurogenesis in the hippocampus29<\/sup>. Due to increased lifetime\u00a0expectancy, now-a-days Alzheimer\u2019s has become a public health load30<\/sup>. Many studies reported that the pathogenesis of Alzheimer\u2019s disease includes elevated acetylcholinesterase levels and increased oxidative stress that are found to be associated with enhanced levels of\u00a0protein carbonyls, lipid peroxidation and decreased superoxide dismutase activity, levels of reduced glutathione and the activity of catalase in the hippocampus of rodents. The prevalence and severity of the disease motivated us to reconnoiter the abilities of medicinal\u00a0plants to manage this illness.Our results showed that chronic administration of scopolamine influences different regions of brain that affects the spatial learning and cognition by increasing acetylcholinesterase activity and oxidative stress. In the current study, 14 days pre-treatment of animals with Cocculus hirsutus\u00a0<\/em>leaf extractat different doses proved to have neuroprotective potentials that significantly reduces the effects induced by scopolamine as an\u00a0indication from improvement in behavior and neurobiochemical scores of acetylcholinesterase, reduced glutathione and catalase.<\/p>\n

Morris water navigation test was used as behavioral task for assessing visual short-term memory and visual-spatial learning in rats. The results on 7th<\/sup> day, 10th<\/sup> day and 14th<\/sup> day shows that donepezil and Cocculus hirsutus\u00a0<\/em>leaf extract significantly reduces the time taken to reach\u00a0submerged hidden flatform (ELT) from a fixed quadrant in scopolamine induced rats.Our results with Morris water maze test confirmed that leaf extract counteracted the scopolamine induced cognitive deficits thus Cocculus hirsutus<\/em>is a neuroprotective.<\/p>\n

The elevate plus maze test for exteroceptive learning and memory usually based on natural rejection of rodents to high and open spaces. Transfer latency time was considered as the parameter to evaluate acquisition and memory retention in rodents. Generally, the animals\u00a0exhibited shortened transfer latency time in the retention trial as compared to acquisition trial for entering into the open arms of elevated plus maze. In this test, 14 days pretreatment with Cocculus hirsutus\u00a0<\/em>leaf extract significantly reduced the transfer latency time in the rats treated\u00a0with scopolamine as compared with the standard drug donepezil. Our results clearly suggested that Cocculus hirsutus<\/em>has neuroprotective effect because it enhances learning and retention of memory.<\/p>\n

Neurobiochemical results shows that administration of scopolamine for 14 consecutive days markedly increase the degradation of acetylcholine by increasing the acetylcholinesterase activity and diminishes reduced glutathione levels and catalase which gives a measure of\u00a0lipid peroxidation (oxidative stress) in rats brain. Pretreatment of rats with 200 mg\/kg and 400 mg\/kg of Cocculus hirsutus\u00a0<\/em>leaf extract significantly increases the levels of acetylcholine due to decreased acetylcholinesterase activity and enhances reduced glutathione levels and\u00a0catalase activity as a sign of reduced oxidative stress in the brains induced by scopolamine.\u00a0This Cocculus hirsutus\u00a0<\/em>leaf extract proved to have neuroprotective activity in accordance with the results obtained.<\/p>\n

Conclusion<\/strong><\/p>\n

The possible outcomes of this study indicate that Cocculus hirsutus\u00a0<\/em>leaf extract counteracted the impairment of memory and oxidative stress induced by scopolamine. Therefore, it could be inferred that Cocculus hirsutus\u00a0<\/em>can be an appreciated plant resource for age-related\u00a0dementia management. More molecular studies are required to investigate the mechanisms underlying the neuroprotective effects of Cocculus hirsutus\u00a0<\/em>by targeting the other hypothesis of Alzheimer\u2019s.<\/p>\n

Acknowledgement<\/strong><\/p>\n

The authors are grateful to the management K L College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, A.P. and Vignan Institute of Pharmaceutical Technology, Visakhapatnam, A.P. for the facilities granted for the research work.<\/p>\n

Conflict of interest\u00a0<\/strong><\/p>\n

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Renner U. D,Oertel R andKirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit<\/em>.,27(5):655-665 (2005).
    \n    CrossRef<\/a><\/li>\n
  2. Martin L and Andrew J. T. The muscarinic antagonist\u2019s scopolamine and atropine are competitive antagonists at 5-HT3<\/sub> Neuropharmacology<\/em>,108:220-228 (2016).
    \n    CrossRef<\/a><\/li>\n
  3. Sahreh S and Mohammad A. M. Diosmin is neuroprotective in a rat model of scopolamine-induced cognitive impairment. Biomed Pharmacother.<\/em>,108:1376-1383 (2018).
    \n    CrossRef<\/a><\/li>\n
  4. Bajo R, Pusil S, Lopez M. E, Canuet L, Pereda E, Osipova D, et al<\/em>. Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer\u2019s disease. Sci rep<\/em>.,5:9748 (2015).
    \n    CrossRef<\/a><\/li>\n
  5. Atul P, Pranay S, Preeti P, Rajesh S. Y and Prakash C. B. Scopolamine induced behavioral and biochemical modifications and protective effect of Celastruspaniculatous<\/em> and Angelica glauca<\/em> in rats. Int J NutrPharmacolNeurol Dis.,<\/em>4(3):158-169 (2014).
    \n    CrossRef<\/a><\/li>\n
  6. Samaila M. C, Che Norma M. T, Mohamad Aris M. M, Mohamad Taufik H. B, Zulkhairi A andSaravanan J. The use of nootropics in Alzheimer\u2019s disease: is there light as the end of the tunner?.Biomed Res Ther.,<\/em>6(1):2937-2944 (2019).
    \n    CrossRef<\/a><\/li>\n
  7. Amira M, Shuntaro Y, Yoshinori K andKuniyoshi S. In vitro <\/em>Neuroprotective Activities of Compounds from Angelica Shikokiana<\/em> Molecules,<\/em>20:4813-4832 (2015).
    \n    CrossRef<\/a><\/li>\n
  8. Bindhu K. H and Vijayalakshmi A. Neuroprotective effect of Carica papaya <\/em>leaf extract against aluminium toxicity: An experimental study on cognitive dysfunction and biochemical alteration in rats. Indian J Pharm Educ.,<\/em>53(3 Suppl 2):s392-s398 (2019).
    \n    CrossRef<\/a><\/li>\n
  9. Smith M. A, Perry G, Richey P. L, Sayre L. M, Anderson V. E, Beal M. F, et al<\/em>. Oxidative damage in Alzheimer\u2019s. Nature,<\/em>382(6587):120-121 (1996).
    \n    CrossRef<\/a><\/li>\n
  10. Jeffrey L. C, Travis M and Kate Z. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther.,<\/em>6:37 (2014).
    \n    CrossRef<\/a><\/li>\n
  11. Kumar H, More S. V, Han S. D, Choi J. Y and Choi D. K. Promising therapeutics with natural bioactive compounds for improving learning and memory \u2013 A review of randomized trials. Molecules,<\/em>17:10503-10539 (2012).
    \n    CrossRef<\/a><\/li>\n
  12. Satish V, Ravichandrian V. D, Usha G andPadmaa M. P. Antimicrobial studies on the extracts of Cocculus hirsutus <\/em> and Hyptissuaveolens<\/em>Poit. Indian J Nat Prod Resour., <\/em>1:49-52 (2010).<\/li>\n
  13. Logesh R, Das N, Adhikari-Devkota A andDevkota H. P. Cocculus hirsutus <\/em>(L.) W. Theob. (Menispermaceae): A review on traditional uses, phytochemistry and pharmacological activities. Medicines, <\/em>7(11):69 (2020).
    \n    CrossRef<\/a><\/li>\n
  14. Nayak S. K andSinghai A. K. Anti-inflammatory and analgesic activity of roots of Cocculus hirsutus.Indian J Nat Prod., <\/em>9:12-14 (1993).<\/li>\n
  15. Ganapaty S and Vijay K. Hypoglycemic activity of aerial parts of Cocculus hirsutus<\/em> on alloxan-induced diabetes. Indian J Nat Prod., <\/em>22:17-20 (2006).<\/li>\n
  16. Singh S. K, Sinha S. K andShirsat M. K. Design, synthesis and evaluation of 4-Aminopyridine analogues as Cholinesterase inhibitors for management of Alzheimer\u2019s diseases. Indian J Pharm Educ.,<\/em>52(4):644-654 (2018).
    \n    CrossRef<\/a><\/li>\n
  17. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods.,<\/em>11(1):47-60 (1984).
    \n    CrossRef<\/a><\/li>\n
  18. Raghavendra M, Rituparna M, Kumar S and Acharya S. B. Role of Ocimum sanctum<\/em> in the experimental model of Alzheimer\u2019s disease in rats. Int J Green Pharm.<\/em>,3(1):6-15 (2009).
    \n    CrossRef<\/a><\/li>\n
  19. Kulkarni P. D, Ghaisas M. M, Chivate N andSankpal P. S. Memory enhancing activity of Cissampelospariera<\/em> in mice. Int J Pharm Pharma Sci.,<\/em>3(2):206-211 (2011).<\/li>\n
  20. Yamini N, AfsarSh, Devi K, Deepak K, Premalatha S and Pavan K. B. Effect of ethanolic seed extract of Bauhinia purpurea<\/em> on cognition in scopolamine induced Alzheimer\u2019s disease rat\u2019s model. J Compr Pharm.,<\/em>2(4):145-150 (2015).
    \n    CrossRef<\/a><\/li>\n
  21. Gauresh S. S, Mruniya S. N, Aakash D. P, Mandar B. M, Priya J. G, Kirti S. L and Sadhana S. Neuroprotective effect of Cubebin: A dibenzylbutyrolactonelignan on scopolamine-induced amnesia in mice. Indian J Med Res.,<\/em>146(2):255-259 (2017).
    \n    CrossRef<\/a><\/li>\n
  22. Flohe L and Gunzler W. A. Assays of glutathione peroxidase.,<\/em>105:114-121 (1984).
    \n    CrossRef<\/a><\/li>\n
  23. Aebi H. Catalase in vitro.Methods Enzymol.,<\/em>105:121-126 (1984).
    \n    CrossRef<\/a><\/li>\n
  24. Ellman G. L, Courtney K. D, Valentino A. J and Robert M. F. A new and rapid colorimetric determination of acetylcholinesterase activity. ,<\/em>7(2):88-90 (1961).
    \n    CrossRef<\/a><\/li>\n
  25. Leopold F andWolfgand A. G. Assays of glutathione peroxidase. Methods Enzymol.,<\/em>105:114-120 (1984).
    \n    CrossRef<\/a><\/li>\n
  26. Asru K. S. Colorimetric assay of catalase. Anal Biochem.,<\/em>47(2):389-394 (1972).
    \n    CrossRef<\/a><\/li>\n
  27. Mundugaru R, Sivanesan S, Udaykumar P, Vidyadhara D, Prabhu S. N and Ravishankar B. Neuroprotective functions of Alpinia galanga <\/em>in forebrain ischemia induced neuronal damage and oxidative insults in rat hippocampus. Indian J Pharm Educ.,<\/em>52(4S):s77-s85 (2018).
    \n    CrossRef<\/a><\/li>\n
  28. Jewart R. D, Green J, Lu C. J, Cellar J and Tune L. E. Cognitive, behavioral and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry.,<\/em>13(4):324-328 (2005).
    \n    CrossRef<\/a><\/li>\n
  29. Demars M, Hu Y. S, Gadadhar A and Lazarov O. Impaired neurogenesis is an early event in the etiology of familial Alzheimer\u2019s disease in transgenic mice. J Neurosci Res.,<\/em>88(10):2103-2117 (2010).
    \n    CrossRef<\/a><\/li>\n
  30. Kalaria R. N, Maestre G. E, Arizaga R, Friedland R. P, Galasko D, Hall K, et al<\/em>. Alzheimer\u2019s disease and vascular dementia in developing countries: prevalence, management and risk factors. Lancet Neurol.,<\/em>7(9):812-826 (2008).
    \n    CrossRef<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction 6,7-Epoxytropine tropate (Scopolamine), also known as Hyoscine, is a […]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[93],"tags":[],"class_list":["post-40090","post","type-post","status-publish","format-standard","hentry","category-vol14no3"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/40090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=40090"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/40090\/revisions"}],"predecessor-version":[{"id":41291,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/40090\/revisions\/41291"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=40090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=40090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=40090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}